Objective-Evening but not morning administration of low-dose aspirin has been reported to lower blood pressure in hypertensive patients. The present study was designed to determine whether this phenomenon could be replicated in mice, and if so, whether a time-dependent effect of aspirin on blood pressure was because of alteration of circadian clock function. Approach and Results-We recapitulated the protective effect of aspirin (50 μg/d for 7 days) at zeitgeber time 0 (activeto-rest transit), but not at zeitgeber time 12, on a high-salt diet-induced increase of blood pressure. However, the time of aspirin administration did not influence expression of canonical clock genes or their acetylation. We used mouse Bmal1 and Per2-luciferase reporters expressed in U2OS cells to determine the real-time effect of aspirin on circadian function but found that the oscillation of bioluminescence was unaltered. Timing of aspirin administration also failed to alter urinary prostaglandin metabolites or catecholamines, or the acetylation of its COX-1 (cyclooxygenase-1) target in platelets. Conclusions-The time-dependent hypotensive effect of aspirin in humans has been recapitulated in hypertensive mice.
A spirin is most often used at low doses (≈100 mg/d) in the secondary prevention of myocardial infarction and stroke, 1,2 an effect explained sufficiently by its inhibition of formation of thromboxane A 2 , the predominant product of COX (cyclooxygenase)-1 in platelets. 3 Higher doses of aspirin are necessary to inhibit COX-2 and thereby relieve pain and inflammation. Deletion of COX-2 accelerates thrombogenesis and elevates blood pressure (BP). 4 Interestingly, knockdown of COX-1, that simulates the pharmacological effect of low-dose aspirin in mice, not only delays thrombogenesis, but also restrains the elevation of BP caused by COX-2 inhibition. 5 In humans, several controlled clinical trials have reported that low-dose aspirin reduces BP in hypertensive populations, but only when given in the evening, [6] [7] [8] [9] raising the possibility that this effect may contribute to its cardiovascular benefit in hypertensive populations. 6 However, most patients continue to take aspirin in the morning. This may reflect caution emanating from a failure to replicate these findings that mostly derive from the work of one group of investigators 10 and a failure to identify a mechanism that might explain this phenomenon. Recently, administration of low-dose (150 mg/ day) aspirin in the evening was reported to reduce the incidence of preeclampsia in a susceptible population, 11 but the study did not include a control group given aspirin in the morning.
Here we wished to determine if we could recapitulate this phenomenon in mice, better to address potential mechanism. Given the broad-ranging impact of the molecular clock on drug targets and drug disposition 12, 13 and the influence of the clock on BP 14 and its regulatory mechanisms 15, 16 we wondered if this might explain an antihypertensive effect of aspirin conditioned by the time of dosing. As aspirin can acetylate proteins beyond platelet COX-1 17 and because that the function of some core clock proteins can be modulated by acetylation, 18, 19 we hypothesized that a direct impact of aspirin on the circadian clock might explain its time-dependent effects on BP.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. December 2018
Experimental Design for BP Recording
Twelve-week-old male C57BL/6 mice acclimatized to a 12/12-hour light/dark cycle for 1 week before radiotelemetry implantation. Although our studies were confined to male mice, the clinical reports of time-dependent hypotensive effects of low-dose aspirin are evident in both genders. The basal BP and heart rate (HR) recordings began 7 days after this operation. Mice were subjected to a high-salt diet (HSD, 8% NaCl) for 2 weeks to evoke a hypertensive response, better to clarify the phenotype, then divided randomly into 2 groups and treated with aspirin (50 μg/d in 100 μL of water) by gavage at zeitgeber time (ZT) 0 or ZT12 for 7 consecutive days followed by BP recording. Urine was collected for 24 hours using metabolic cages after each BP recording. At the end of the experiment, mice were euthanized by CO 2 inhalation for tissue sample collections ( Figure 1 ). Samples were stored at −80°C until use.
A separate set of HSD-and aspirin-treated mice was used for analysis of gene expression assay. Tissue samples were collected at ZT8 and ZT20 after 2-, 4-, or 8-day treatment of aspirin. In addition, another set of mice treated with HSD for 4 weeks was used, but for in vivo experiments only, including measurements of BP, HR, and locomotor activity. All procedures were approved by the University of Pennsylvania IACUC and the Animal Center at Dalian Medical University, Dalian, China.
Telemetry Recordings
Under general anesthesia, PA-C10 telemetry probes (Data Sciences, St Paul, MN) were implanted in the carotid artery as previously described.
14 Telemetry recordings began 7 days after surgery. Continuous BP and HR were monitored in unrestricted animals with the use of the Dataquest IV system (Data Sciences).
Urinary Prostaglandin Metabolites and Catecholamines
Systemic production of prostaglandin (PG) D 2 , PGE 2 , PGI 2 , and thromboxane A 2 was determined by mass spectrometric quantitation of their major urinary metabolites: PGD-M, PGE-M, PGI-M, and thromboxane-M, respectively as previously described. 20 Epinephrine, norepinephrine, and dopamine were measured using Elisa (17-TCTHU-E03.1, Alpco Immunoassays) following the manufacturer's instruction. Data were corrected for urinary creatinine.
Quantitative Reverse Transcription Polymerase Chain Reaction
Total RNA from aorta, heart, kidney, and adrenal gland was extracted using RNeasy kit (QIAGEN) following the manufacturer's instructions. The concentration of RNA was measured by Nanodrop (Thermo Scientific). A total of 0.5 μg of each sample was applied reverse transcription with reagents obtained from Applied Biosystem. TaqMan Universal PCR Master Mix and probes (Applied Biosystems) for 18s rRNA, COXs, and core clock genes, Bmal1, Clock, Npas2, Rev-erbα, Per1, Per2, Cry1, Cry2, were used for real-time polymerase chain reaction.
Immunoprecipitation and Western Blot
MOVAS (a mouse aorta smooth muscle cell line) and SVEC4-10 cells (a mouse vascular endothelial cell line) were obtained from American Type Culture Collection (CRL-2797 and -2181, respectively). Primary culture of mouse aorta smooth muscle cells was described previously. 21 At 80% confluence, the cells, grown in a 12-well plate, were treated with 1 mmol/L aspirin for 24 hours, and then lysed in cell extraction buffer (Catalog No. FNN0011, Invitrogen). The cell lysates were applied for immunoprecipitation using rabbit antibodies (bmal1, sc-48790, Santa Cruz; Ac-Lysine, 9814, Cell Signaling Technology) and Dynabeads Protein G (100.03D, Invitrogen) following manufacturer's instruction. The precipitated proteins were eluted using NuPAGE LDS sample buffer (NP0007, Invitrogen) containing a reducing agent (NP0004, Invitrogen) at 70°C. The eluted samples were then resolved by SDS-PAGE gel, transferred to polyvinylidene fluoride membranes (LC2002, Invitrogen) and analyzed by using antibodies against bmal1, Ac-lysine, and p53 (sc-126, Santa Cruz). As negative controls, immunoprecipitation was performed in the absence of antibody or in the presence of rabbit IgG.
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blood pressure COX cyclooxygenase HR heart rate HSD high-salt diet PG prostaglandin ZT zeitgeber time Figure 1 . Study design for blood pressure (BP) recording. Basal BP of 14-wk-old mice was recorded using radiotelemetry followed by 2-wk high-salt diet (HSD) treatment. BP was recorded after HSD and mice were then treated with aspirin (ASA) at zeitgeber time (ZT) 0 (A) or ZT12 (B) for 7 consecutive days followed by BP recording. Urine was collected after each BP recording. At the end of the experiment, mice were euthanized for tissue collection.
Quantification of COX-1 Acetylation by Aspirin
Mice were treated with 50 μg aspirin by gavage at ZT0 or ZT12. Blood samples were collected 0.5 or 24 hours after treatment and platelets were isolated for measurement of COX-1 acetylation by isotope dilution mass spectrometry in multiple reaction monitoring mode as previously described. 22 Briefly, mouse COX-1 specific sequence (MGAPFSLK) and its acetylated form [MGAPFS(+ace)LK] were measured by their unique transitions on a TSQ Vantage triple stage quadrupole mass spectrometer (Thermo Scientific) interfaced with a Nano-ACQUITY UPLC system (Waters). Quantification information was extracted from the peak areas of the transitions using Xcalibur QuanBrowser (Thermo Scientific). COX-1 acetylation was calculated using the ratio of peak area of the acetylated peptide divided by total peak area of nonmodified peptide and modified peptide.
Clock Gene Oscillation by Bioluminescence
A clonal line of human osteosarcoma U2OS cells, stably expressing Bmal1-Luc or Per2-Luc reporters was generously provided by John Hogenesch (Cincinnati Children's Hospital Medical Center). Cells were grown in the DMEM medium supplemented with 10% fetal bovine serum, 0.3 mg/mL L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin. For the luminescence recording, the cells were seeded in 3.5 cm dishes in culture medium with addition of 0.1 mmol/L luciferin and 0.1 μmol/L dexamethasone. The luminescence was recorded by an automated robotic system (GNF Systems) equipped with a charge-coupled device imager (ViewLux, PerkinElmer).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 7. All statistical tests were 2-sided. Kruskal-Wallis 1-way ANOVA and a subsequent Dunn multiple comparisons test were used when a single variable was compared between 2 or more groups, 2-way ANOVA with Sidak multiple comparisons when 2 variables were compared between groups, and 3-way ANOVA with Tukey multiple comparisons test when 3 variables exist as recommended by the software. The cutoff for significance was *P<0.05, **P<0.01, and ***P<0.001. In all figures with error bars unless specified, the graphs depict means±SEM.
Results
Administration of Aspirin at the Active/ Inactive Transition Has a Protective Effect on HSD-Induced Increase of BP
Two weeks on the HSD increased systolic BP from 101.2±0.9 to 110.6±1.9 mm Hg (P<0.05). Mice were then randomly allocated to aspirin (50 μg/d) by gavage once per day for 7 consecutive days at times equivalent to awakening (ZT12) or bedtime (ZT0) while maintained on the HSD. The HSD continued to increase systolic BP in the group given aspirin at ZT12 (110.5±4.1 versus 116.1±5.4 mm Hg, P=0.09; Figure 2A ) with a difference that was more pronounced during the light phase (104.6±4.1 versus 112.4±5.1 mm Hg, P<0.05; Figure 2B ). However, when we administered aspirin at ZT0, the rise in systolic BP was absent (110.8±1.2 versus 108.9±2.9 mm Hg). This effect was not accompanied by changes of body weight ( Figure 2C ). After 4 weeks on the HSD, aspirin treatment at ZT0 lowered systolic BP in both light and dark phases (Figure 3) , and mean arterial pressure, HR, and locomotor activity in the light phase, while no obvious change was found in those dosed at ZT12 (Table) . Thus, we recapitulated the time-dependent hypotensive effect of aspirin in HSD-treated mice.
No Time-Dependent Effect of Aspirin on the Expression of Circadian Genes in Mouse Heart, Aorta, Kidney, or Adrenal Gland
At the end of the in vivo experiments, we collected several organs relevant to BP regulation, including heart, aorta, kidney, and adrenal gland at ZT8 and ZT20 when both Bmal1 and its reciprocal core clock partner, Rev-erbα, show differential gene expression. 12 We found no evidence that time of aspirin dosing differentially impacted expression of the 01; n=6-7) . B, The increase of SBP in ASA-ZT12 group was more pronounced during the light phase. (2-way ANOVA; *P<0.05; n=6-7.) C, There is no statistical difference in body weight between the ASA-ZT0 and ASA-ZT12 dosing groups (2-way ANOVA; n=10).
canonical clock genes, Bmal1, Clock, Npas2, Rev-erbα, Per1, Per2, Cry1, or Cry2 at either ZT8 or ZT20 at the end of the study (Figure 4) . To address the possibility that there might have been a reversible impact on clock genes at an earlier stage in the dosing period, we performed another experiment in which mice were euthanized for tissue collection at multiple time points. As shown in Figure I in the online-only Data Supplement, among all comparisons between aspirin-ZT0 and aspirin-ZT12, only Per2 in the heart collected on day 4 showed a statistical difference, noted at ZT8.
Aspirin Failed to Influence Directly the Molecular Clock
We found that P53 was acetylated or its acetylation was increased by aspirin in MOVAS and SVEC4-10 cells. Acetylation of Bmal1 was also detected; however, the pattern was not affected by aspirin ( Figure 5A ). None of the other clock proteins, including Clock, Per1, Per2, Cry1, and Cry2, were found acetylated by aspirin treatment. Acetylation of platelet COX-1, the mechanism by which aspirin prevents thrombosis, was unaltered by time of drug administration ( Figure 5B ). Using Bmal1-Luc and Per2-Luc reporter expressing U2OS cell lines, aspirin (0.1, 0.5, and 2 mmol/L), failed to alter the period, amplitude, or phases of the oscillating bioluminescence rhythms ( Figure 6 ).
No Time-Dependent Effect of Aspirin on Urinary PG Metabolites or Catecholamines
Aspirin administered at both ZT0 and ZT12 decreased PG biosynthesis as reflected by the urinary metabolites, PGD-M, PGE-M, PGI-M, and thromboxane-M. However, this impact was unaltered by the time of dosing ( Figure 7A ). There was Figure 4 . mRNA levels of core clock genes in the kidney, heart, aorta, and adrenal gland were revealed by quantitative reverse transcription polymerase chain reaction. All data were normalized to 18s rRNA. There is no obvious difference between aspirin (ASA)-zeitgeber time (ZT) 0 and ASA-ZT12 groups in any examined tissues collected either at ZT8 or ZT20 (2-way ANOVA; n=5-6). also no time-dependent difference in epinephrine or norepinephrine when measured at the end of the study. Dopamine was lower on aspirin, but there was no difference between aspirin-ZT0 and aspirin-ZT12 ( Figure 7B ).
Discussion
It has long been known that BP and HR are subject to circadian rhythmicity; indeed, the failure of BP to fall at night (nondipping) has been associated with poor cardiovascular clinical outcomes. 23 These time-dependent effects are not just consequences of the sleep/wakefulness cycle but are believed to be attributable to intrinsic properties of the cardiovascular system that fluctuate under the control of the molecular clock during the course of the day. 24, 25 During the past 2 decades, Hermida et al 8, [26] [27] [28] [29] [30] [31] have reported several randomized trials in hypertensive populations in which low-dose aspirin (100 mg) administered at night but not in the morning lowered BP in both genders. Recently, in a multicenter, double-blind, placebo-controlled trial, Rolnik et al 11 found that treatment with 150 mg aspirin at night in women at risk reduced the incidence of preterm preeclampsia, however, they did not control for time of drug administration. Despite these observations, there have been reasons for skepticism. First, some groups have failed to reproduce the fundamental finding. 10, 32 Second, there is no mechanistic explanation for the phenomenon.
In the current study, we first recapitulated the time-dependent effect of aspirin on human BP in mice. As in humans, aspirin lowered BP in hypertensive mice when administered at the transition between activity and rest. Ironically, replication of this phenotype in a model system lends credence to the veracity of the phenomenon in humans. Given the prevalence of hypertension and the effectiveness and commonality of aspirin consumption for the secondary prevention of cardiovascular disease, a population-based shift to evening dosing might have a considerable effect on cardiovascular outcomes. Interestingly, there was no apparent baroreflexmediated increase in HR coincident with the aspirin mediated time-dependent reduction in BP. 28, 30 Here both HR and activity were decreased by aspirin treatment at ZT0 and this may have contributed to the BP lowering effect in mice. Here we saw no impact of aspirin on urinary epinephrine and norepinephrine. Although urinary dopamine was reduced on aspirin, there was no time-dependent effect apparent. In future studies, we intend to elucidate further the potential contribution of autonomic function, as well as addressing other signaling pathways that may underlie these observations. Urinary prostaglandin (PG) metabolites (A) and catecholamines (B) were measured using mass spectrometry and Elisa, respectively, (2-way ANOVA; *P<0.05; **P<0.01; ***P<0.001; n=9-11). Data were normalized to creatinine. ASA indicates aspirin; DOP, dopamine; EPI, epinephrine; NE, norepinephrine; Tx, thromboxane; and ZT, zeitgeber time.
Indeed, this model affords a more tractable opportunity to address mechanism. The current studies suggest that it does not involve a direct effect of aspirin on the core molecular clock. The time of aspirin administration does not obviously influence expression of a variety of clock genes in heart, aorta, kidney, or adrenal gland, tissues of direct relevance to BP regulation and cardiovascular homeostasis. Aspirin prevents thrombotic events by acetylating platelet COX-1 but is recognized potentially to acetylate additional proteins. 17 Although some clock proteins can be modulated by acetylation, 33 aspirin did not alter the acetylation patterns of Bmal1 in cultured mouse vascular smooth muscle cells or endothelial cells in vitro. None of the other clock proteins that we studied, including Clock, Per1, Per2, Cry1, and Cry2, were acetylated by aspirin treatment. Besides, platelet COX-1 acetylation did not differ at 0.5 or 24 hours after aspirin treatment at ZT0 or ZT12. Furthermore, aspirin did not alter the oscillation of bioluminescence in U2OS cells expressing Bmal1 and Per2-luciferase reporters. Finally, although rhythmic histone acetylation underlies transcription in the mammalian circadian clock, 34 it is not acetylated by aspirin. 35 These results fail to support the hypothesis that the time-dependent effect of aspirin is attributable to a direct action on circadian clock.
Aspirin prevents thrombotic events like myocardial infarction by cumulatively acetylating platelet COX-1 dependent thromboxane A 2 formation when administered at low doses that have minimal impact on COX-2-derived PGs like PGI 2 3 . Here the biochemical profile of the dose of aspirin we selected (suppression of urinary metabolites of PGs of the E, D, and I series along with thromboxane) more closely resembles that of anti-inflammatory doses of aspirin in humans. None of the trials of time-dependent aspirin administration in humans have used such higher doses although our recapitulation of the functional phenotype (and the failure to implicate platelet COX-1) suggests that the phenomenon may be independent of aspirin dose.
Our findings seem to contrast with the attenuation of the fall in BP during the rest phase in mice globally deficient in COX-1. 36 This may reflect differences in genetic background and variability in tissue distribution of aspirin, as well as an oscillation in its targets that at this dose would involve both COX-1 and COX-2.
In summary, the time-dependent impact of aspirin on BP in hypertensive patients was recapitulated in mice made hypertensive by an HSD. This does not result from a direct effect of aspirin on core clock gene expression or oscillation. Recapitulation of this time-dependent effect in mice lends weight to the clinical observation and the argument to advise evening dosing with low-dose aspirin by hypertensive patients who take it for cardioprotection.
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